Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line

Cancer Gene Therapy volume 23, pages 254–257 (2016)Cite this article

Subjects

Abstract

Prostate cancer usually develops to a hormone-refractory state that is irresponsive to conventional therapeutic approaches. Therefore, new methods for treating aggressive prostate cancer are under development. Because of the importance of androgen receptors (ARs) in the development of the hormone-refractory state and AR mechanism of action, this study was designed. A single-stranded DNA as an aptamer was designed that could mimic the hormone response element (HRE). The LNCaP cells as an AR-rich model were divided into three sets of triplicate groups: the test group was transfected with Aptamer Mimicking HRE (AMH), Mock received only transfection reagents (mock) and a negative control. All three sets received 0, 10 and 100 nM of dehydroepiandrosterone (DHEA) separately. Data analysis showed hormone dependency of LNCaP cells in the negative control group upon treatment with 10 and 100 nM DHEA (compared with cells left untreated (P=0.001)). Transfection of AMH resulted in significant reduction of proliferation in the test group when compared with the negative control group with 10 (P=0.001) or 100 nM DHEA (P=0.02). AMH can form a hairpin structure at 37 °C and mimic the genomic HRE. Hence, it is capable of effectively competing with genomic HRE and interrupting the androgen signaling pathway in a prostate cancer cell line (LNCaP).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin 2012; 65: 87–108.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A . Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.

    Article  Google Scholar 

  3. Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brucher B et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer 2014; 5: 3–24.

    Article  CAS  Google Scholar 

  4. Gann PH . Risk factors for prostate cancer. Rev Urol 2002; 4 (Suppl 5): S3–S10.

    PubMed  PubMed Central  Google Scholar 

  5. Chang AJ, Autio KA, Roach M 3rd, Scher HI . High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 2014; 11: 308–323.

    Article  Google Scholar 

  6. Marciscano A, Hardee M, Sanfilippo N . Management of high-risk localized prostate cancer. Adv Urol 2012; 2012: 641689.

    Article  Google Scholar 

  7. Graff JN, Chamberlain ED . Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid 2015; 10: 1–10.

    CAS  PubMed  Google Scholar 

  8. Knudsen KE, Scher HI . Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15: 4792–4798.

    Article  CAS  Google Scholar 

  9. Lonergan PE, Tindall DJ . Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011; 10: 20.

    Article  CAS  Google Scholar 

  10. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA . Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000; 275: 10638–10647.

    Article  CAS  Google Scholar 

  11. Haelens A, Verrijdt G, Callewaert L, Peeters B, Rombauts W, Claessens F . Androgen-receptor-specific DNA binding to an element in the first exon of the human secretory component gene. Biochem J 2001; 353: 611–620.

    Article  CAS  Google Scholar 

  12. Kim YS, Gu MB . Advances in aptamer screening and small molecule aptasensors. Adv Biochem Eng Biotechnol 2014; 140: 29–67.

    CAS  PubMed  Google Scholar 

  13. Song KM, Lee S, Ban C . Aptamers and their biological applications. Sensors (Basel) 2012; 12: 612–631.

    Article  Google Scholar 

  14. Diafa S, Hollenstein M . Generation of aptamers with an expanded chemical repertoire. Molecules 2015; 20: 16643–16671.

    Article  CAS  Google Scholar 

  15. Wang Y, Luo Y, Bing T, Chen Z, Lu M, Zhang N et al. DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. PLoS One 2014; 9: e100243.

    Article  Google Scholar 

  16. He X, Chen J, Yie SM, Ye SR, Dong DD, Li K . Using a sequence of estrogen response elements as a DNA aptamer for estrogen receptors in vitro. Nucleic Acid Ther 2015; 25: 152–161.

    Article  CAS  Google Scholar 

  17. Chaturvedi S, Garcia JA . Novel agents in the management of castration resistant prostate cancer. J Carcinog 2014; 13: 5.

    Article  Google Scholar 

  18. Schroder FH . Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008; 53: 1129–1137.

    Article  Google Scholar 

  19. Li MT, Richter F, Chang C, Irwin RJ, Huang H . Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor. BMC Cancer 2002; 2: 16.

    Article  Google Scholar 

  20. Devlin HL, Mudryj M . Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009; 274: 177–186.

    Article  CAS  Google Scholar 

  21. Pickard MR, Mourtada-Maarabouni M, Williams GT . Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013; 1832: 1613–1623.

    Article  CAS  Google Scholar 

  22. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV . RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003; 63: 3799–3804.

    CAS  PubMed  Google Scholar 

  23. Deezagi A, Ansari-Majd S, Vaseli-Hagh N . Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA. Clin Transl Oncol 2012; 14: 791–799.

    Article  CAS  Google Scholar 

  24. Liao X, Tang S, Thrasher JB, Griebling TL, Li B . Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005; 4: 505–515.

    Article  CAS  Google Scholar 

  25. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL . Androgen-regulated processing of the oncomir miR-27a, which targets prohibitin in prostate cancer. Hum Mol Genet 2012; 21: 3112–3127.

    Article  CAS  Google Scholar 

  26. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer 2010; 9: 12.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Ilnaz Rahimmanesh and Ariel Morris for their kind collaboration.

Author information

Authors and Affiliations

  1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

    S Kouhpayeh & A Rezaei

  2. Department of Biology, International Pardis, University of Guilan, Rasht, Iran

    A R Einizadeh & M Sojoudi

  3. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

    Z Hejazi, L Shariati, M Mirian, L Darzi & H Khanahmad

  4. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

    M Boshtam

  5. Isfahan Pharmaceutical Science Research Center, School of Pharmacy and Pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, Iran

    H Khanahmad

Authors
  1. S Kouhpayeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A R Einizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z Hejazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Boshtam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Shariati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Mirian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Darzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Sojoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Khanahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Rezaei.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kouhpayeh, S., Einizadeh, A., Hejazi, Z. et al. Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line. Cancer Gene Ther 23, 254–257 (2016). https://doi.org/10.1038/cgt.2016.26

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2016.26

This article is cited by

Search

Advanced search

Quick links